498
Participants
Start Date
July 29, 2020
Primary Completion Date
September 24, 2026
Study Completion Date
September 24, 2026
GDC-6036
The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
Atezolizumab
A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
Cetuximab
Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
Bevacizumab
A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
Erlotinib
150 mg of erlotinib will be administered PO QD in 21 day cycles.
GDC-1971
The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
Inavolisib
The starting dose of inavolisib will be determined from its single-agent dose escalation.
Auckland City Hospital, Cancer and Blood Research, Auckland
Hôpitaux Universitaires de Genève, Geneva
St Vincent's Hospital Sydney, Darlinghurst
Slade Health Inward goods, Mount Kuring-Gai
UZ Antwerpen, Edegem
AZ St Maarten Campus Leopoldstr, Mechelen
Peter MacCallum Cancer Center, Melbourne
Alfred Health, Melbourne
Inselspital, Bern
Clinexpert Gyongyos Kft, Gyöngyös
CHU de Liège, Liège
Haukeland University Hospital, Bergen
Linear Clinical Research Limited, Nedlands
Memorial Sloan Kettering Cancer Center, New York
Seoul National University Bundang Hospital, Seongnam-si
UPMC - Hillman Cancer Center, Pittsburgh
Abramson Cancer Center, Philadelphia
Istituto Clinico Humanitas, Rozzano (MI)
Irccs Ospedale San Raffaele, Milan
Asst Grande Ospedale Metropolitano Niguarda, Milan
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario HM Sanchinarro-CIOCC, Madrid
Hospital Clinico Universitario Virgen de la Victoria, Málaga
Florida Cancer Specialists - Sarasota, Sarasota
Hospital Universitario Virgen del Rocío, Seville
Hospital Clinico Universitario de Valencia, Valencia
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS, Meldola
Sheba Medical Center - PPDS, Ramat Gan
Azienda Ospedaliero Universitaria Pisana, Pisa
University of Oklahoma, Oklahoma City
City of Hope Comprehensive Cancer Center, Duarte
UCSD Moores Cancer Center, La Jolla
Chao Family Comprehensive Cancer Center UCI, Orange
Rambam Medical Center, Haifa
Tel-Aviv Sourasky Medical Center, Tel Aviv
Yale Cancer Center, New Haven
Dana Farber Cancer Institute, Boston
Santa Casa de Misericordia de Belo Horizonte - PPDS, Belo Horizonte
Hospital Erasto Gaertner, Curitiba
Hospital de Clinicas de Porto Alegre HCPA PPDS, Pôrto Alegre
Universidade de Caxias do Sul, Caxias do Sul
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre
Hospital de Cancer de Barretos, Barretos
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, São José do Rio Preto
Instituto Nacional de Câncer, Rio de Janeiro
Ottawa Hospital, Ottawa
Princess Margaret Cancer Centre, Toronto
Jewish General Hospital, Montreal
Aga Khan University Hospital, Nairobi
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
Leids Universitair Medisch Centrum, Leiden
Maastricht University Medical Center, Maastricht
Universitair Medisch Centrum Utrecht, Utrecht
Auckland City Hospital, Auckland
New Zealand Clinical Research - Christchurch, Christchurch
Oslo university hospital Radiumhospitalet, Oslo
Uniwersyteckie Centrum Kliniczne, O?rodek Bada? Klinicznych Wczesnych Faz, Gdansk
Biokinetica, Przychodnia Jozefow, Józefów
Seoul National University Hospital, Seoul
Asan Medical Center - PPDS, Seoul
Samsung Medical Center - PPDS, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Queen Elizabeth Hospital, Birmingham
Velindre Cancer Centre, Cardiff
University College London Hospitals NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Genentech, Inc.
INDUSTRY